【摘 要】
：
Cancer stem cells are considered as an origin of cancer.Cancer stem cells can cause tumors in mice models.Recent studies proved the efficacy of some promising therapies to treat cancers.Dendritic cell
【机 构】
：
Animal Physiology and Biotechnology Laboratory, Stem Cell Research and Application Laboratory Vietna
【出 处】
：
BITs 3rd Annual World Cancer Congress-2012(2012第五届世界癌症大会)
论文部分内容阅读
Cancer stem cells are considered as an origin of cancer.Cancer stem cells can cause tumors in mice models.Recent studies proved the efficacy of some promising therapies to treat cancers.Dendritic cell (DC) therapy is one of the best promising therapies to treat cancer.In recent years, DC therapy is performed by using primed cancer cell antigens of DC to immune organism body.This research aims to combine DC therapy with breast cancer stem cell (BCSC)antigen for treating breast cancer and compare the treatment efficacy of DC therapies with BCSCs and breast cancer cells derived antigens in murine models.DCs were derived from mouse bone marrow monocytes.Then they were loaded with the breast cancer cell antigen prior to employ into the tumor mice model.This was performed to determine whether the DCs would capture and eventually migrate, be present in the spleen and present the cancer antigens to autologous CD8 T cells;induce the activation of the CTL response.The existence and size of tumors in mice was evaluated after 15-60 days from transplantation.The results showed that 5/15;10/15, 5/15 mice of the experimental group with injected BCSC antigen, breast cancer antigen, and BCSC-breast cancer antigen mixture loaded DCs respectively got tumors after 20 transplantation days.While in control group 15/15 mice got tumors after 10 transplantation days.It is also noticed that transplanted DCs could migrate into spleen, stimulate CD8 T ceils and CD45 T cells proliferation.Specially, the ratio of CD8 T cells strongly increased in comparison to control or normal mice.These results are important and provides most required initial platform to do further experiment.Results of this study also established a promising novel targeting therapy for cancer, especially for breast cancer.
其他文献
Circulating tumor cells (CTCs) obtained noninvasively can be used as a surrogate for primary tumor cells.Indeed,CTCs are likely derived from clones in the primary tumor, suggesting that they can be us
Epithelial-mesenchymal transition (EMT) plays a central role in both physiological and pathological settings including embryogenesis, wound healing, stem cell transformation and tumor metastasis.Durin
Rituximab is a chimeric anti-CD20 antibody of IgG 1 class, with human kappa light-chain constant regions and murine light-and heavy-chain variable regions.CD20 is expressed on mostly all stages of B c
Detection and quantification of genetic mutations from circulating tumor cells (CTC) and cell free tumor DNA (ctDNA)may provide a noninvasive means for early cancer detection and disease monitoring.Ho
The role of circulating tumor cells (CTCs) has begging to be recognized the last few years.Still during time several approaches have been developed in purpose to identify, enumerate and analyze these
A major problem associated with current cancer therapeutics is the eventual recurrence even after the elimination of bulk of the cancer cells.Recent studies on cancer stem cells may provide a potentia
Tumor initiation and progression are driven by a subpopulation of tumor cells that possess stem cell properties and are resistant to traditional cancer treatments—the cancer stem cells (CSCs).CSCs hav
Deregulated activation of tyrosine kinases plays an important role in the initiation and propagation of many hematological and solid tumors.Lapatinib is a highly selective dual inhibitor of ErbB2 (HER
We previously found that the expression of inhibitor of differentiation 1 (ID1) was elevated in breast cancer cells after long-term exposure to fulvestrant, an antagonist of ESR1.In this study, we dem
Imprime PGG(R) Injection (Imprime PGG) is an immunomodulatory beta-glucan polymer isolated from a proprietary stain of Saccharomyces cerevisiae that selectively binds to complement receptor 3 (CR3) on